Grassley Says $465M EpiPen Settlement Likely Shortchanges Taxpayers

The Department of Justice announced Thursday (Oct. 17) an EpiPen settlement of $465 million, which is the same amount DOJ denied having settled on last October when EpiPen maker Mylan announced the deal. Senate Judiciary Chair Charles Grassley (R-IA) said it appears the settlement “shortchanges” taxpayers. The company agreed to the settlement to resolve U.S. Attorney’s Office allegations that Mylan violated the False Claims Act by knowingly misclassifying the branded epinephrine auto-injector drug as a generic drug to avoid paying...